🔗 Share this article

As America continues making unprecedented revisions to its vaccination guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders were set to announce radical changes to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US at odds with much of the world with insufficient data for benefit. The announcement has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

A Shift at the FDA

The acting appointment could signify a tighter collaboration between the drug and vaccine centers as Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for ending some childhood shot schedules in the US in order to be more in line with Denmark, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has little discernible track record in drug development, regulation or leadership, which has been typical for previous directors of the CBER. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “grasp legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

This division has an enormous workload at the FDA, she stated.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and so forth, and all of those must be looked after,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a significant administrative aspect to the position, which oversees over 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” she added.

Agency Reaction and Controversial Programs

When asked about inquiries about Dr. Høeg's credentials and whether this selection represents increased cooperation among agency officials on immunizations, a representative said that the “concerns rely on flawed assumptions”.

“Her resume matches the functions of her position,” the spokesperson stated, pointing to the months Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's recently launched fast-track approval initiative, a disputed expedited therapy clearance system that allegedly concerned her former heads. “How are these therapies being selected for this voucher program? Who takes the decisions?” Howard said. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards laxer oversight of pharmaceuticals, except for shots.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, past, Howard said. She published a study using unverified volunteer-provided data to assess the incidence of myocarditis after Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming government encompassed altering guidelines for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has according to sources suggested preventing young men from receiving Covid vaccines.

“She is an thorough dogmatist who commences with her beliefs and tailors the evidence to accommodate the science in a very deceptive, untruthful way,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|